IRMA study protocol. Breast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs. standard radiotherapy after conserving surgery
Indication
Locoregional
Subindication
Not applicable
Target sample size
3302
Actual accrual
3302 (NL 830)
Date: 05/02/2019
Estimated study completion date
01/07/2018
Contact
Sponsor
Modena University Hospital
Principal Investigator(s)
Ph. Poortmans-L.J. Boersma
Study manager
A.E. van Leeuwen-Stok
Central datamanagement and randomization
Clinical Trials Office, University of Modena Tel. +39 059 422 3865 roberto.vicini@unimore.it
Monitoring
Quality assurance RT via dummy runs
Local datamanagement
IKNL
Funding
Funding KWF-CKS
Design
Randomization: Experimental arm: 38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days. Control arm: 45 Gy/18 fractions, or 50 Gy/25 fractions, or 50,4 Gy/28 fractions, or iso-effective fraction schemes, once a day for 5 days a week. A 10 – 16 Gy boost is allowed in centers where it is part of the standard treatment.
Objectives
To evaluate whether partial hypofractionated and accelerated irradiation of the sole surgical cavity, in patients suffering from breast cancer with low risk of local recurrence and undergoing conservative surgery, is not inferior to postoperative irradiation with conventional fractionation of the entire breast as regards local control, measured in terms of incidence of ipsilateral recurrences as first event.
Endpoints
Primary endpoint:
Local ipsilateral recurrence as first event free survival
Secondary endpoints:
Overall survival
Locoregional recurrence-free survival
Distant recurrence-free survival
Acute and late toxicity (RTOG)
Cosmetic result
Eligibility Criteria
Female, pT 1-2 (< 3 cm in diameter) pN0-N1 M0 Unifocal Histologically negative resection margins (≥ 2 mm) at first intervention or after subsequent widening Undergoing conservative breast surgery for invasive breast cancer